Why I'm Doubling Down on This Biotech Company...

Taking a Look at a Potential Leader in Biosimilars (CHRS) & Weekly Activity

This Weeks Newsletter is Powered by Savvy Trader!

I’ve transitioned to Savvy Trader’s platform for more transparency and real-time tracking of my portfolio. Attached below is the link to my portfolio on Savvy Trader:

https://savvytrader.com/SteveWagsInvest/stevewagsinvest

If this has issues connecting, search for “Steve Wagner | Invest” as your 2nd option. Doing this, you should be able to find my portfolio. This is 100% FREE and will start putting more time into that platform.

A Diamond in the Rough?

Investors that have been following me for the past month and a half, know how aggressive I’ve been accumulating in a couple businesses in the biotechnology realm. One of those names is Relay Therapeutics (RLAY), and one other I’ve been pounding the table on for weeks… that business is called Coherus BioSciences (CHRS). I’ve deployed thousands and thousands of dollars into this company over the past month and a half, after being on my watchlist for many months before. CHRS has now been obliterated in this market, not noticing it's significant catalysts on the horizon (almost inevitable to happen), making it extremely undervalued. It started with the delays for Toripalimab, now dilution with M&A activity of Surface Oncology (SURF), which have all been blown way out of proportion. This has now moved up to the same conviction level as WM, LMND, UPST, & RCEL in my portfolio. So, let’s dive into CHRS and identify why I’m “Doubling Down” on this biosimilar.